Gilead's Kite files for FDA approval of second CAR-T therapy

Gilead’s Kite has filed for FDA approval of its second CAR-T cell therapy. Kite hopes to win approval for KTE-X19 in mantle cell lymphoma on the strength of midphase results linking it to a 67% complete response rate.